Posts

Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty

on

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

on

Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push

on

Gilead's Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

on

AbbVie's Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials

on

Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix

on

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

on

AbbVie's Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

on

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

on

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

on

FDA Delays Decisions on Regeneron’s Eylea HD Due to Manufacturing Issues

on

Tariffs and MFN Policy Power a Broad, Confusing Pharma War

on

Stealth BioTherapeutics Resubmits Third FDA Application for Rare Disease Drug

on